You may remember Part I of this blog that focused on the experiences of two PatientsLikeMe members who attended the Kidney Health Initiative’s (KHI) workshop, “Understanding patients’ preferences: Stimulating medical device development in kidney disease,” back in August. KHI is a partnership between the U.S. Food and Drug Administration (FDA) and the American Society of… Continue reading Getting “Patients Included” right Part II: Planning a patient-centric event
Tag: ASN
Getting “Patients Included” right Part I: Two members attend a Kidney Health Initiative workshop
Back in August, the Kidney Health Initiative (KHI), a partnership between the U.S. Food and Drug Administration (FDA) and the American Society of Nephrology (ASN), held a workshop called “Understanding patients’ preferences: Stimulating medical device development in kidney disease.” But this was more than a workshop – it was an event centered around the idea… Continue reading Getting “Patients Included” right Part I: Two members attend a Kidney Health Initiative workshop
Comparing Our Transplants Community to the UNOS/OPTN Databases
Last November (2010), PatientsLikeMe was fortunate to have the opportunity to showcase our research at the world’s largest gathering of kidney and kidney transplant professionals. The American Society of Nephrology (ASN) annual meeting is the premiere event platform for debuting revolutionary treatments, cutting-edge technological breakthroughs and top research findings. PatientsLikeMe presented a poster about our… Continue reading Comparing Our Transplants Community to the UNOS/OPTN Databases
Share and Compare: A PatientsLikeMe Year in Review (Part II – R&D)
The PatientsLikeMe research and development (R&D) team is excited about what we can all share and learn in 2011. Here’s a look back at some of what patients like you shared with us, and what we then shared with the world, in 2010. The R&D team published and presented some unprecedented insights based on what… Continue reading Share and Compare: A PatientsLikeMe Year in Review (Part II – R&D)